Would you treat PSA-only disease in a 65-year-old man with PSA of 10 ng/mL?Would you treat PSA-only disease in a 65-year-old man with PSA of 10 ng/mL?Would you recommend treatment (versus observation) for a 65-year-old patient with an undetectable PSA after local therapy, but 3 years later the PSA level measures 10 ng/mL and the PSA doubling time (PSADT) was less than 3 months? Would you administer treatment if the PSADT were 6 months? 12 months? (Note that workup reveals no metastatic disease.)
Hampson LA et al. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol 2015;[Epub ahead of print]. Abstract Loblaw DA et al. American Society of Clinical Oncology Clinical Practice Guidelines: Formal systematic review-based consensus methodology. J Clin Oncol 2012;30(25):3136-40. Abstract Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: Evolving standards of care and new directions. Clin Adv Hematol Oncol 2013;11(1):14-23. Abstract Rove KO et al. Role of testosterone in managing advanced prostate cancer. Urology 2012;80(4):754-62. Abstract Sartor O et al. The COMPARE Registry: Design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. Urology 2010;75(3):623-9. Abstract |